PT - JOURNAL ARTICLE AU - Jill Hollenbach AU - Michael J. Ombrello AU - Adriana Tremoulet AU - Jaime S. Rosa Duque AU - Gilbert T. Chua AU - Gonzalo Montero-Martin AU - Jane C. Burns AU - Chisato Shimizu AU - Gail Deutsch AU - Dimitri Monos AU - Vamsee Mallajosyula AU - Jianpeng Xu AU - Debopam Ghosh AU - Serena Tan AU - Elaine Remmers AU - Scott Canna AU - Ann Marie Szymanski AU - Danielle Rubin AU - Marcelo A. Fernandez-Vina AU - Vivian E. Saper AU - Elizabeth D. Mellins AU - Drug Hypersensitivity in sJIA Consortium investigators TI - Hypersensitivity reactions to IL-1 and IL-6 inhibitors are linked to common HLA-DRB1*15 alleles AID - 10.1101/2020.08.10.20172338 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.10.20172338 4099 - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20172338.short 4100 - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20172338.full AB - In Saper et al (2019), we described systemic JIA patients who developed a high-fatality diffuse lung disease (DLD) while on IL-1 or IL-6 inhibitors. We observed severe delayed drug hypersensitivity reactions (DHR) in a significant subset. Because alleles of the human leukocyte antigen (HLA) loci can mediate DHR, we investigated HLA genotype association with these DHR. We typed subjects treated with these inhibitors: 34 sJIA/DHR/DLD, 11 sJIA/DHR without DLD, 18 drug-tolerant sJIA, and 19 Kawasaki disease (KD) patients in an anti-IL-1(anakinra) trial. We also accessed genotypes from a large sJIA case/control cohort.We first compared White subjects with sJIA/DHR to 550 ancestry-matched sJIA subjects. We found striking enrichments of HLA-DRB1*15:01, HLA-DQA1*01:02, and DQB1*06:02, alleles in near-complete linkage (White individuals). HLA-DRB 1*15:01 (as haplotype proxy) was increased in White sJIA subjects with DHR/DLD versus sJIA drug-tolerant controls and was observed upon inclusion of sJIA+DHR-only and KD+DHR White subjects. In our entire cohort regardless of ancestry, 75% carried HLA-DRB 1*15:01 or the structurally related DRB1*15:03 and DRB1*15:06, which were absent among drug-tolerant subjects (p=5 x 10-13; Odds Ratio lower bound=20.11).Patients who harbor HLA-DRB1*15 alleles are at high risk of developing DHR to anti-IL-1/IL-6. Our data also suggest DHR maybe a trigger/enhancer of DLD in sJIA patients and support performing prospective HLA screening in sJIA, its adult-onset counterpart, and other inflammatory conditions where these drugs are used, such as KD.Competing Interest StatementVES reports personal fees from Novartis. GD reports personal fees from Novartis. SC reports personal fees from Novartis and grants from AB2 Bio. GS reports personal fees from Novartis. AAG reports grants and personal fees from Novartis and grants from NovImmune. SL reports personal fees from Novartis. SS reports personal fees from Novartis. MLS reports personal fees from Novartis. EDM reports grants from Novartis.Funding StatementThe work was supported by Lucile Packard Foundation for Children's Health, the Gordon and Marilyn Macklin Foundation, RK Mellon Institute for Pediatric Research and the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Stanford University's institutional review board (#13932 and #34679) and by local review boards from contributing institutions as needed, based on local practice. Informed consent was obtained, as required, for HLA genotyping or sharing of available genetic data for each participant. The study also was approved by the Institutional Review Board of the NIH, and parents and subjects provided written informed consent/assent, as appropriate. The study also was approved by the Institutional Review Board at the University of California San Diego, and parents and subjects signed written consent and assent as appropriate.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript will be available upon reasonable request.